Elevance Health reported strong first-quarter 2026 earnings, with adjusted EPS of $12.58, exceeding analysts' expectations by 17.8%. Following this performance, Bank of America upgraded the stock rating from Neutral to Buy, setting a target price of $435. Although the company has seen a 13.91% share decline over the past year, it recently announced an increase in its full-year EPS guidance and launched a $1.1 billion stock repurchase program. Despite these positive developments, Elevance continues to grapple with projected challenges in Medicaid margins, forecasting a negative operating margin of -1.75%.
Loading timeline…